NCT00006002 2013-09-05
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
University of Chicago
Phase 2 Completed
Clinical Trials
12 trialsNCT00006013 2013-07-11
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
Fox Chase Cancer Center
Phase 2 Completed
NCT00026260 2013-06-24
SU5416 in Treating Patients With Persistent or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006001 2013-06-03
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00006014 2013-06-03
SU5416 in Treating Patients With Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005862 2013-02-11
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00017316 2013-02-11
Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006003 2013-01-24
SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00009919 2013-01-23
SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00006384 2011-10-20
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00006361 2009-12-04
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005931 2005-06-24
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment
NIH AIDS Clinical Trials Information Service
Phase 2 Completed